Enavogliflozin 是一种口服有效的，选择性的钠-葡萄糖协同转运体 -2 抑制剂，具有抗糖尿病的功效。

Enavogliflozin is an orally available small molecule and sodium glucose transporter 2 inhibitor.

Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 ( SGLT-2 ) inhibitor[1][2][3].

1415472-28-4

C24H27ClO6

446.92

DWP-16001

DMSO:100 mg/mL (223.75 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years